Retrovirus Epidemiology Donor Study-II (REDS II) Molecular Surveillance (MS) - Catalog

  • Name

    Retrovirus Epidemiology Donor Study-II (REDS II) Molecular Surveillance (MS)

  • Accession Number

    HLB00961212a

  • Acronym

    REDS II-MS

  • Related studies
  • BSI Study IDs
  • Is public use dataset

    False

  • Keywords
  • Ingestion Status
    Released
  • Has Study Datasets

    True

  • Has Specimens

    False

  • Specimen ID Type
    Not Applicable (Data Only)
  • Study Website
  • The Framingham Heart Study Group requires that the requestor must obtain full or expedited IRB/Ethics Committee review and approval to obtain these data. Waivers or a determination that the research is exempt from ethical regulations do not suffice.

    False

  • Clinical Trial URLs
    NCT00097006
  • Study type
    Epidemiology Study
  • Collection Type
    Open BioLINCC Study
  • Cohort type
    Adult
  • Interventions
  • Study Open Date (Data)

    2012-11-19

  • Study Open Date (Specimens)

    2012-11-19

  • Date materials available

    2012-11-16

  • Last updated

    2019-05-10

  • Study period

    2006 - 2009

  • Study Contacts
  • NHLBI Division

    DBDR

  • Classification
    Transfusion Medicine
  • HIV study classification
    HIV
  • COVID study classification
    non-COVID
  • Pre-Website # of Specimens Shipped

    0

  • # of Returned Specimens

    0

  • Primary Publication URLs
    22293432
  • Commercial use data restrictions
    No
  • Data restrictions based on area of research
    No
  • Commercial use specimen restrictions
    Not Applicable (Data Only)
  • Non-genetic use specimen restrictions based on area of use
    Not Applicable (Data Only)
  • Genetic use of specimens allowed?
    Not Applicable (Data Only)
  • Genetic use area of research restrictions
    Not Applicable (No Genetic Use Specimens)
  • Specific Consent Restrictions
  • Conditions
    Acquired Immunodeficiency Syndrome
    Blood Donors
    Blood Transfusion
    HIV Infections
    HIV-1
    HIV-2
    HTLV-I
    HTLV-II
    Hepacivirus
    Hepatitis B
    Hepatitis, Viral, Human
    Retroviridae Infections
    West Nile Virus
  • Objectives

    The objective of the study was to conduct a genetic analysis of incident and prevalent strains of HIV, HCV and HBV by testing blood specimens from HIV, HCV or HBV positive blood donors who gave blood at REDS-II centers, as well as at UBS, NYBC and ARC blood centers between 2006 and 2009.

  • Background

    Genetic variations of human immunodeficiency virus (HIV), hepatitis C virus (HCV), and hepatitis B virus (HBV) can affect diagnostic assays and therapeutic interventions. Recent changes in prevalence of subtypes/genotypes and drug/immune-escape variants were characterized by comparing recently infected vs. more remotely infected blood donors.

  • Participants

    This study included qualifying donations from 1 January 2006 through 31 December 31 2009 from 3 Retrovirus Epidemiology Donor Study-II (REDS-II) blood centers (Blood Centers of the Pacific, Blood Center of Wisconsin, and Hoxworth Blood Center/University of Cincinnati), all American Red Cross Blood Services regions, United Blood Services regions and the New York Blood Center. Together, these centers account for approximately 70% of the US blood supply.

  • Design

    Infected donors were identified among approximately 34 million US blood donations, 2006–2009 based on screening and confirmatory tests for HIV and HCV nucleic acid testing, HIV and HCV antibody, HBsAg, and anti-HBV core antibody; incident infections were defined as having no or low antiviral antibody titers. Viral genomes were partially sequenced.

  • Conclusions

    Viral genetic variant distribution in blood donors was similar to that seen in high-risk US populations. Blood-borne viruses detected through large-scale routine screening of blood donors can complement molecular surveillance studies of highly exposed populations. (Delwart et. al. 2012)

  • Disease classification
  • Publications
  • Mat types
  • Network
    Retrovirus Epidemiology Donor Study II (REDS II)

The study population available in BioLINCC study data may be lower than total study enrollment due to Informed Consent restrictions and other factors.

  • Subjects

    12118


    Last Modified: July 28, 2014, 2:40 p.m.
  • Age
     FrequencyPercent
    16-20144211.90
    21-258977.40
    26-308777.24
    31-358156.73
    36-4010388.57
    41-45142911.79
    46-50200216.52
    51-55185615.32
    56-6010358.54
    61-653793.13
    66-701791.48
    71-75930.77
    76-80490.40
    81-85160.13
    >=86110.09

    Last Modified: Oct. 31, 2023, 1:18 p.m.
  • Sex
     FrequencyPercent
    NOT AVAILABLE30.02
    FEMALE436636.03
    MALE774963.95

    Last Modified: Oct. 31, 2023, 1:18 p.m.
  • Race
     FrequencyPercent
    REFUSED40.03
    NOT AVAILABLE262121.63
    ASIAN9667.97
    BLACK182315.04
    HISPANIC9187.58
    NATIVE AMERICAN910.75
    WHITE535244.17
    MORE THAN ONE RACE570.47
    OTHER2862.36

    Last Modified: Oct. 31, 2023, 1:18 p.m.